SENTINEL ONCOLOGY LIMITED

05336536
Active Cambridge

Research and experimental development on biotechnology

6 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
S

SENTINEL ONCOLOGY LIMITED

05336536

Research and experimental development on biotechnology

Founded 19 Jan 2005 Active Cambridge, England 6 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 17 Dec 2025 Next due 31 Dec 2026 5 months remaining
Confirmation Submitted 27 Aug 2025 Next due 6 Sept 2026 2 months remaining
Net assets £5M £689K 2024 year on year
Total assets £5M £870K 2024 year on year
Total Liabilities £221K £182K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

181 Science Park Milton Road Cambridge Cambridgeshire CB4 0GJ England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for SENTINEL ONCOLOGY LIMITED (05336536), an active life sciences and medical technology company based in Cambridge, England. Incorporated 19 Jan 2005. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Apr → 31 Mar 2025
Type total-exemption-full
Next accounts 31 Mar 2026
Due by 31 Dec 2026 5 months remaining

Net Assets, Total Assets & Total Liabilities (2014–2024)

Cash in Bank

£4.68M

Decreased by £875.85k (-16%)

Net Assets

£4.72M

Decreased by £688.61k (-13%)

Total Liabilities

£220.71k

Decreased by £181.62k (-45%)

Turnover

N/A

Employees

6

Increased by 1 (+20%)

Debt Ratio

4%

Decreased by 3 (-43%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Mar Year End
2024
31 Mar Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 1
Grants 2

Investors (1)

Investor NameInvestor SinceParticipating Rounds
Investor 4Jan 2005Seed

Officers

Officers

2 active 1 resigned
Status
John DixonDirectorBritishUnited Kingdom801 Feb 2010Active
Stuart TraversSecretaryBritishUnknown20 May 2006Active

Shareholders

Shareholders (19)

Mtmh Consulting Sa
21.9%
1,723,000
The Wellcome Trust Limited As Trustee Of The Wellcome Trust
18.0%
1,417,000

Persons with Significant Control

Persons with Significant Control (2)

2 Active

Robert George Boyle

British

Active
Notified 29 Jan 2025
Residence England
DOB October 1971
Nature of Control
  • Significant Influence Or Control

Stuart Travers

British

Active
Notified 29 Jan 2025
Residence England
DOB June 1968
Nature of Control
  • Significant Influence Or Control

Group Structure

Group Structure

SENTINEL ONCOLOGY LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
17 Dec 2025AccountsAnnual accounts made up to 31 Mar 2025
27 Oct 2025OfficersChange to director Mr Robert George Boyle on 10 Oct 2025
27 Aug 2025Confirmation StatementConfirmation statement made on 23 Aug 2025 with no updates
29 Jan 2025Persons With Significant ControlRobert George Boyle notified as a person with significant control
29 Jan 2025Persons With Significant ControlStuart Travers notified as a person with significant control
17 Dec 2025 Accounts

Annual accounts made up to 31 Mar 2025

27 Oct 2025 Officers

Change to director Mr Robert George Boyle on 10 Oct 2025

27 Aug 2025 Confirmation Statement

Confirmation statement made on 23 Aug 2025 with no updates

29 Jan 2025 Persons With Significant Control

Robert George Boyle notified as a person with significant control

29 Jan 2025 Persons With Significant Control

Stuart Travers notified as a person with significant control

Recent Activity

Latest Activity

Annual accounts made up to 31 Mar 2025

6 months ago on 17 Dec 2025

Change to director Mr Robert George Boyle on 10 Oct 2025

8 months ago on 27 Oct 2025

Confirmation statement made on 23 Aug 2025 with no updates

10 months ago on 27 Aug 2025

Robert George Boyle notified as a person with significant control

1 years ago on 29 Jan 2025

Stuart Travers notified as a person with significant control

1 years ago on 29 Jan 2025